Lung Cancer
Conditions
Keywords
neoadjuvant therapy
Brief summary
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
Interventions
Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital; 2. At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery; 3. Malignancy was present and confirmed in the pathology before treatment and after surgery; 4. The lung lesion was the primary lesion.
Exclusion criteria
1. No lung surgery was performed until 2022.11; 2. No preoperative neoadjuvant therapy was performed or recorded; 3. Neoadjuvant therapy did not include immune drugs; 4. Previous history of malignancy (including surgery and adjuvant therapy); 5. Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 2017-2023 | Progression-free defined as status of recurrence of lung cancer |
| Overall survival (OS) | 2017-2023 | Overall defined as the living status, alive or dead |
Countries
China
Outcome results
None listed